World Health Organization guidelines were consulted when defining study covariates and outcomes. Patients with MDR-TB were participants with Mycobacterium tuberculosis isolates resistance to at least isoniazid and rifampicin. A positive sputum culture was defined as Mycobacterium tuberculosis colony growth and a negative sputum culture as no colony growth [9] . Sputum culture conversion was defined as two consecutive negative cultures, collected at least 30 days apart. Sputum culture reversion to positive was defined as one or more subsequent positive results after initial conversion. Sensitivity was defined as the proportion of patients with sputum culture conversion among those with treatment success. Specificity was defined as the proportion of patients with nonconversion of sputum culture among those with poor outcome. Sensitivity of culture conversion was used as a predictor of treatment success and specificity of lack of culture conversion as a predictor of failure/death. Final outcomes included success, failure and death. End-of-treatment success was defined as completion of treatment or cure. Adverse outcomes were treatment failure or death. Sputum smear grading was as follows: 1+ (3-9 acid-fast bacilli (AFB) in 100 fields), 2+ (1-9 AFB in 10 fields), 3+ (1-9 AFB in 1 field) and 4+ (⩾10 AFB in 1 field). Smear grade was dichotomised ⩽1 (included smear-negative and 1+) and >1 (included smear-positive 2+, 3+, 4+).
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Cox proportional hazards modelling was used to estimate hazard ratios, with sputum culture conversion as the end-point. Kaplan-Meier survival curves were plotted (not shown), and differences between groups were estimated by the log-rank test. Odds ratios and Chi-squared tests were used to determine associations between conversion and treatment outcome.
Of 160 patients with pulmonary MDR-TB enrolled, 139 had recorded treatment outcomes. Median age was 51 (interquartile range (IQR) 35.8-60.0) years; median weight was 60 (IQR 53.0-65.0) kg; 99 (71.4%) were male; 65 (46.8%) had smoked previously or were current smokers at the time of treatment, and 26 (18.7%) drank alcohol. Of 139 patients with MDR-TB, 84 (60.4%) patients had a successful treatment outcome and 55 (39.6%) either experienced treatment failure or died. In all, 106 (76.3%) patients had sputum culture conversion. Median time to culture conversion among those who converted was 159 (IQR 127-212) days. Overall, the median sputum culture conversion time of patients with successful treatment outcomes was 92 days (95% CI 85-99 days), which was much shorter ( p<0.001) than for the patients with treatment failure or death (174 days, 95% CI 0-513). 2-month conversion was not statistically significantly associated with treatment success ( p=0.087). However, patients who converted sputum culture at 3 ( p=0.007), 6 ( p<0.001) and 24 months ( p<0.001) had increased odds of treatment success compared to nonconverters. The overall sensitivity of sputum culture conversion at 2, 3, 6 and 24 months was 33.3%, 52.4%, 90.5% and 95.2%, respectively. The specificity of these markers was 80.0%, 70.9%, 56.4% and 52.7%, respectively (table 1).
Earlier detection of participant nonresponse to treatment may allow clinicians to adjust treatment protocols and, subsequently, avoid poor outcomes [10] . A recent study conducted by MITNICK et al. [2] demonstrated that monthly sputum culture outperformed bimonthly collection of sputum smear and culture in detecting patients with MDR-TB that failed treatment. These findings highlight the specific value of performing a prospective cohort study to investigate the efficacy of sputum culture conversion after different durations of MDR-TB treatment.
Anti-TB pharmacological treatment is adjusted according to the culture conversion of patients, resulting in decreased rates of adverse effects by reducing the number of given injectable drugs [11] . Furthermore, prolonging conversion time may increase the chance that patients transmit TB to other individuals in their social network. Therefore, sputum culture conversion has not only clinical significance but also important public health relevance. In the current study, sputum culture conversion at 2 months was not statistically associated with treatment success, whereas patients with sputum culture conversion at 3, 6 and 24 months had a significantly higher likelihood of treatment success compared with those who did not convert. Data from 12 randomised trials of patients with drug-susceptible tuberculosis suggested that 3-month culture conversion was superior to 2-month conversion as a surrogate for poor treatment outcome, but neither were ideal [12] . Although 2-month culture conversion is generally considered an early predictor of treatment success in patients with MDR-TB, its low sensitivity in detecting long-term treatment success is a cause for concern. A recent study by KURBATOVA et al. [9] suggested that the overall association between culture conversion and treatment success is substantially stronger at 6 months compared with 2 months due to higher sensitivity. Our study corroborates this finding and also shows substantially lower specificity when evaluating treatment success at 6-versus 2-month culture conversion (specificity, 56.4% versus Data are presented as n (%), unless otherwise stated. # : sputum culture conversion was defined as two consecutive negative cultures after the first sputum sample, collected at least 30 days apart. PPV: positive predictive value; NPV: negative predictive value.
https://doi.org/10.1183/13993003.01558-201680.0%). Our results suggest an intricate balance between high and low sensitivity and specificity, depending on the time point at which sputum culture testing occurs.
The low sensitivity at 2-and 3-month culture conversion suggests that many patients would be misclassified as having failed treatment, thereby underestimating overall therapeutic efficacy. Furthermore, such misclassification would result in replacement of effective drugs and termination of a potentially successful drug regimen. In our study, sputum culture conversion at 2 months had a sensitivity of 33.3%, indicating that 66.7% of patients would be misclassified. However, the specificity for sputum culture conversion at the end of 6 months of treatment was 56.4%, indicating that 43.6% of patients would be misclassified as effectively treated. These results indicate that missed opportunities to replace a more effective drug regimen for patients failing treatment is common, and may contribute to high death rates among patients with drug-resistant tuberculosis. Surrogate end-points should take into account the balance between predicting treatment success and failure accurately during treatment of drug resistance [9] . In our study, time to sputum culture conversion at 6 months was significantly associated with end-of-treatment outcomes. The high combined sensitivity and specificity was reached for sputum culture conversion status assessed at 6 months of treatment. Given the average 50-60% prevalence of treatment success reported in MDR-TB cohorts worldwide [13, 14] , PPVs were relatively high: 75.5% for 6-month sputum culture conversion. Sputum culture conversion at 6 months may be a crucial indication for trials conducted to determine a highly effective and inexpensive standardised treatment.
In summary, our study suggests that sputum conversion at 6 months had a much higher sensitivity, but a substantially lower specificity, to predict MDR-TB treatment success compared with sputum conversion at 2 and 3 months.
